New EU guidance aims to simplify safety reporting for studies of products that combine a drug and diagnostic or a drug and medical device, but sponsors still face duplicate reporting requirements for serious adverse events under separate frameworks.
New EU guidance aims to simplify safety reporting for studies of products that combine a drug and diagnostic or a drug and medical device, but sponsors still face duplicate reporting requirements for serious adverse events under separate frameworks.